mRNA: Delivering an antitumor message?

Immunotherapy

Volumn 3, Issue 5, 2011, Pages 605-607

  Van Lint, Sandra ^a   Thielemans, Kris ^a   Breckpot, Karine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

cancer; immunotherapy; mRNA; TLR

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMORAL IMMUNITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 79955910863     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.28     Document Type: Article

References (17)

1. Wolff JA, Malone RW, Williams P et al.: Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1), 1465-1468 (1990).
2. Conry RM, LoBuglio AF, Wright M et al.: Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55(7), 1397-1400 (1995).
3. Hoerr I, Obst R, Rammensee HG, Jung G: In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30(1), 1-7 (2000). (Pubitemid 30011760)
4. Granstein RD, Ding W, Ozawa H: Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J. Invest. Dermatol. 114(4), 632-636 (2000). (Pubitemid 30226992)
5. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184(2), 465-472 (1996). (Pubitemid 26324100)
6. Tuyaerts S, Michiels A, Corthals J et al.: Induction of influenza matrix protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther. 10(9), 696-706 (2003). (Pubitemid 37129457)
7. Van Meirvenne S, Straetman L, Heirman C et al.: Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther. 9(9), 787-797 (2002). (Pubitemid 34971310)
8. Bonehill A, Heirman C, Tuyaerts S et al.: Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 172(11), 6649-6657 (2004). (Pubitemid 38669100)
9. Bonehill A, Tuyaerts S, Van Nuffel AM et al.: Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol. Ther. 16(6), 1170-1180 (2008). (Pubitemid 351737084)
10. Aerts-Toegaert C, Heirman C, Tuyaerts S et al.: CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur. J. Immunol. 37(3), 686-695 (2007). (Pubitemid 46916935)
11. + regulatory T cells. J. Leukoc. Biol. 82(1), 93-105 (2007). (Pubitemid 47026420)
12. Tuyaerts S, Aerts JL, Corthals J et al.: Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56(10), 1513-1537 (2007). (Pubitemid 47094397)
13. Weide B, Carralot JP, Reese A et al.: Results of the first Phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31(2), 180-188 (2008).
14. Weide B, Pascolo S, Scheel B et al.: Direct injection of protamine-protected mRNA: results of a Phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32(5), 498-507 (2009).
15. Pascolo S: Vaccination with messenger RNA (mRNA).Handb. Exp. Pharmacol. (183), 221-235 (2008).
16. Fotin-Mleczek M, Duchardt KM, Lorenz C et al.: Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011).
17. Kreiter S, Selmi A, Diken M et al.: Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70(22), 9031-9040 (2010).